John Lambert Elected Chairman of Mucosis
Mucosis B.V. announced that John Lambert was elected as member and chair of its Supervisory Board. Having held various key positions at pharmaceutical and biotech companies in both the United States and Europe, Mr. Lambert brings exceptional vaccine industry experience to Mucosis.
From 1998 to 2000 Mr. Lambert was President at Aventis Pasteur MSD, a vaccine joint venture established between Aventis (now sanofi-aventis Group) and Merck & Co, Inc. Subsequently, from 2001 to 2005, he served as President of Chiron Vaccines (now Novartis Vaccines). Mr. Lambert was a non-executive Director at Acambis Plc (U.K.), chairman of the Conseil d’Administration of Farmaprojects S.A. (Spain), non-executive chairman of Cambridge Biostability Ltd. (U.K.) and advisor for Crucell N.V. (Netherlands) on acquisitions and strategy. He is currently Board Director of Novavax Inc. (U.S.A.).
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Lowering pH regulates spider’s silk production
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany - "This new facility will allow us to better serve our customers and explore new chromatography techniques and applications"
New pharmaceutically active substances from billions of newly combined molecules - “We’re seeing immense interest from industry and research, especially in cyclic molecules, which to date haven’t been accessible in large numbers”
Pharming's Ruconest(TM) for HAE granted European Marketing Authorization
Analytik Jena AG establishes subsidiary in Thailand
Stolze Science & Business Consulting - Hannover, Germany
Sartorius Stedim Biotech and Bosch Packaging Technology Announce Global Collaboration
Bacteria acquire resistance from competitors
HPV may lurk in your throat
The origins and ID of pancreatic endocrine cells - Endocrine stem cells in the pancreas disappear after birth
